Phathom Pharmaceuticals, Inc. Common Stock (PHAT) Stock Price

PHATStock

$6.92−48.01%52W

Market Cap$559.83M

P/E—

PEG Ratio—

Div yield—

Beta0.58

PHAT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-55.29%

Price vs S&P 500 (4W)-5.79%

VGM Score55.02

Book Value / Share (Quarterly)$0.31

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.46

Price vs S&P 500 (YTD)-70.21%

Gross Margin (TTM)82.92%

Net Profit Margin (TTM)-41.34%

EPS (TTM)$-1.27

10-Day Avg Trading Volume1.42M

EPS Excl Extra (TTM)$-1.27

EPS (Annual)$-3.03

ROI (Annual)-88.87%

Gross Margin (Annual)87.09%

Cash / Share (Quarterly)$2.28

Revenue Growth QoQ (YoY)88.02%

ROA (Last FY)-85.37%

Revenue Growth TTM (YoY)110.16%

EBITD / Share (TTM)$-0.52

Operating Margin (TTM)-17.30%

Cash Flow / Share (Annual)$-2.34

P/B Ratio31.81x

P/B Ratio (Quarterly)44.50x

Net Income / Employee (Annual)$-596,400

EV / Revenue (TTM)3.87x

Net Interest Coverage (TTM)-2.62x

ROA (TTM)-35.02%

EPS Incl Extra (Annual)$-3.03

Current Ratio (Annual)1.73x

Quick Ratio (Quarterly)1.82x

3-Month Avg Trading Volume1.30M

52-Week Price Return-48.01%

Revenue / Employee (TTM)$646,000

Tangible BV / Share (Quarterly)$-0.31

P/S Ratio (Annual)3.20x

Asset Turnover (Annual)0.68x

52-Week High$18.31

EPS Excl Extra (Annual)$-3.03

CapEx CAGR (5Y)-26.11%

26-Week Price Return-45.38%

Quick Ratio (Annual)1.58x

13-Week Price Return-36.75%

Total Debt / Equity (Annual)1.24x

Current Ratio (Quarterly)1.92x

Enterprise Value$926.86M

Asset Turnover (TTM)0.85x

Revenue / Employee (Annual)$472,000

Pretax Margin (Annual)-126.35%

Cash / Share (Annual)$1.82

3-Month Return Std Dev71.98%

Net Income / Employee (TTM)$-267,000

ROE (Last FY)-199.28%

Net Interest Coverage (Annual)-0.72x

EPS Basic Excl Extra (Annual)$-3.03

Receivables Turnover (TTM)3.22x

Total Debt / Equity (Quarterly)12.38x

EPS Incl Extra (TTM)$-1.27

ROI (TTM)-17.40%

P/S Ratio (TTM)2.34x

Revenue / Share (Annual)$2.40

Tangible BV / Share (Annual)$-1.80

Forward P/E26.91x

Price vs S&P 500 (52W)-63.54%

Year-to-Date Return-58.29%

5-Day Price Return-2.95%

EPS Normalized (Annual)$-3.03

ROA (5Y Avg)-83.68%

Net Profit Margin (Annual)-126.35%

Month-to-Date Return-5.21%

Cash Flow / Share (TTM)$-3.74

EBITD / Share (Annual)$-2.19

Operating Margin (Annual)-91.36%

LT Debt / Equity (Annual)1.24x

LT Debt / Equity (Quarterly)12.36x

EPS Basic Excl Extra (TTM)$-1.27

P/B Ratio (Annual)8.32x

Inventory Turnover (TTM)7.35x

Pretax Margin (TTM)-41.34%

Book Value / Share (Annual)$2.36

Price vs S&P 500 (13W)-39.43%

Beta0.58x

Revenue / Share (TTM)$2.86

ROE (TTM)-232.78%

52-Week Low$6.52

vGradeC

gGradeA

mGradeD

vgmGradeC

PHAT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	-$0.10	$0.00	+100.00%(+$0.10)
Q1 2026	Apr 30, 2026	-$0.19	-$0.18	+7.34%(+$0.01)
Q4 2025	Feb 26, 2026	-$0.19	-$0.08	+57.45%(+$0.11)
Q3 2025	Oct 30, 2025	-$0.41	-$0.15	+63.86%(+$0.27)
Q2 2025	Aug 7, 2025	-$0.92	-$0.79	+14.36%(+$0.13)

PHAT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.24

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PHATPhathom Pharmaceuticals, Inc. Common Stock	C	A	D	2.3x	110.2%	82.9%	—	$6.92
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Phathom Pharmaceuticals, Inc. Common Stock

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its lead product, vonoprazan, is an oral potassium competitive acid blocker with demonstrated efficacy in treating gastroesophageal reflux disease and Helicobacter pylori infection. The compound exhibits rapid, potent, and durable acid-suppressive effects.